Pharmaceutical News

RSS

New study shows women susceptible to pain-relieving placebo effect of vasopressin

A new study in the current issue of Biological Psychiatry suggests that women are particularly susceptible to the pain-relieving placebo effect of vasopressin.

3 May 2016

Study identifies shortfall in uptake of influenza, pneumococcal vaccination among RA patients

Research from The University of Manchester has found a shortfall in the uptake of influenza and pneumococcal vaccinations among those diagnosed with rheumatoid arthritis (RA), potentially increasing their infection risk.

3 May 2016

Study shows impact of increasing number of opioid-related hospitalizations on health care costs

Infection is a serious complication of intravenous drug abuse and a major cause of illness and death among intravenous drug users. As the national problem of opioid abuse, including of heroin, continues to grow, new research by clinicians at Beth Israel Deaconess Medical Center and the VA Boston Healthcare System, published today in the May issue of the journal Health Affairs, offers new insights into the significant impact of the trend on opioid-related hospitalizations, infectious complications and health care costs.

3 May 2016

Healthy intake of vitamin D contributes to more muscle mass, less body fat in toddlers

A healthy intake of vitamin D in the first year of life appears to set children up to have more muscle mass and less body fat as toddlers, according to a new study published in the journal Pediatric Obesity.

3 May 2016

$Ibrutinib shows added benefit for refractory mantle cell lymphoma patients$

Ibrutinib shows added benefit for refractory mantle cell lymphoma patients

Ibrutinib is a drug for the treatment of rare diseases. It has been approved for the treatment of adults with chronic lymphocytic leukaemia (CLL) or with relapsed or refractory mantle cell lymphoma (MCL) since 2014, and since 2015 also for the treatment of adults with Waldenström macroglobulinaemia. Regarding the treatment of patients with CLL or MCL, the Federal Joint Committee (G-BA) already conducted a benefit assessment and made a decision in 2015.

3 May 2016

Mepolizumab has no hint of added benefit in eosinophilic asthma

The monoclonal antibody mepolizumab has been approved since the end of 2015 for the treatment of adults with severe refractory eosinophilic asthma. The German Institute for Quality and Efficiency in Health Care now examined in an early benefit assessment whether the drug offers an added benefit for patients in comparison with the appropriate comparator therapy.

3 May 2016

Study confirms under-utilization of medication in patients after bypass surgery

Researchers at Thomas Jefferson University discovered that nearly half of coronary artery bypass patients are not taking statins and aspirin together when they are referred for diagnostic cardiac catheterization at least three years after their initial bypass. Their results are currently in press online in the American Journal of Cardiology.

3 May 2016

New nanoparticle approach can deliver antiobesity drugs directly to fat tissue

Researchers at MIT and Brigham and Women's Hospital have developed nanoparticles that can deliver antiobesity drugs directly to fat tissue. Overweight mice treated with these nanoparticles lost 10 percent of their body weight over 25 days, without showing any negative side effects.

3 May 2016

Fish oil supplements combined with anti-cancer therapy can reduce renal cell carcinoma

Researchers at UC Davis have shown that docosahexaenoic acid (DHA), a fatty acid commonly found in fish and fish oil supplements, reduces renal cell carcinoma invasiveness, growth rate, and blood vessel growth when combined with the anti-cancer therapy regorafenib. The study was published in the journal Molecular Cancer Therapeutics.

3 May 2016

Antibiotic treatment may allow bad bugs to flourish

Antibiotics are essential for fighting bacterial infection, but, paradoxically, they can also make the body more prone to infection and diarrhea.

3 May 2016

NEI-funded study analyzes outcomes of anti-VEGF therapy for AMD

In a study of nearly 650 people with the eye disease age-related macular degeneration (AMD), half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with anti-VEGF drugs that are injected into the eye. The authors of the study, funded by the National Eye Institute (NEI) at the National Institutes of Health, say those outcomes would have been unimaginable about 10 years ago, prior to the drugs' availability.

3 May 2016

Hsp90 inhibitors could be effective in treating drug-resistant prostate cancers

Men with aggressive prostate cancer that has stopped responding to conventional treatment could potentially benefit from a new class of cancer drug designed to overcome drug resistance, a new study suggests.

2 May 2016

Small doses of cancer drug may be potential treatment for sepsis and other pandemics

Results from laboratory experiments and mouse studies suggest that small doses of drugs from a specific class of approved cancer medications called topoisomerase 1 (top1) inhibitors may protect against the overwhelming immune response to infection that sometimes leads to sepsis, a bacterial condition that kills as many as 500,000 people in the United States each year.

30 Apr 2016

Scientists unveil reasons why NSAIDs, pain killers may increase heart disease risk

Researchers have known for more than a decade that the risk of heart disease and stroke increases when people take pain relievers like ibuprofen and other non-steroidal anti-inflammatory drugs, or NSAIDs. Now, scientists from the University of California, Davis, have uncovered some of the reasons why these drugs can harm heart tissue.

30 Apr 2016

Promising method may help identify new antimicrobials to target CRE infection

In recent years, hospitals have reported dramatic increases in the number of cases of the highly contagious, difficult-to-treat, and often deadly antibiotic-resistant bacteria carbapenem-resistant Enterobacteriaceae (CRE). Now, investigators at Beth Israel Deaconess Medical Center have developed a promising method of identifying new antimicrobials that target these organisms. The research is published in April issue of the journal ASSAY and Drug Development Technologies.

30 Apr 2016

Nuplazid (pimavanserin) tablets approved to treat hallucinations and delusions

The U.S. Food and Drug Administration today approved Nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson's disease.

30 Apr 2016

New oral cancer drugs getting more expensive over time, study shows

New cancer drugs taken in pill form have become dramatically more expensive in their first year on the market compared with drugs launched 15 years ago, a University of North Carolina at Chapel Hill study has found. The findings call into question the sustainability of a system that sets high prices at market entry in addition to rapidly increasing those prices over time.

30 Apr 2016

First generic version of Crestor gets FDA approval

The U.S. Food and Drug Administration today approved the first generic version of Crestor (rosuvastatin calcium) tablets.

30 Apr 2016

New therapeutic target to treat bacterial infections may substitute antibiotics

Infections continue to threaten human health. With remarkable genetic flexibility, pathogenic organisms outsmart available therapies. Fortunately, microbial versatility is matched by the host immune system, which evolves in dialogue with the microbes. Therapies that enhance the beneficial effects of the immune response represent a promising, but under-explored, therapeutic alternative to antibiotics.

29 Apr 2016

Understanding how individuals respond to aspirin

Researchers have learned new information about how different people respond to aspirin, a globally prescribed drug in cardioprotection. The research team, led by scientists at Cardiff University in the United Kingdom and including representatives from the University of Alabama at Birmingham and the University of Colorado, identified more than 5,600 lipids — or fats — in blood platelets and gained new insights into how these cells respond to aspirin.

29 Apr 2016